Skip to main content
Premium Trial:

Request an Annual Quote

New York Clears Interleukin Genetics' Dental Test

NEW YORK (GenomeWeb News) – Interleukin Genetics has received clearance in the State of New York to offer its genetic test for risk of periodontal disease, the company said today.

The State of New York's Department of Health approved the firm's PST Genetic Test through its Clinical Laboratory Evaluation Program, which monitors the accuracy and reliability of the results of lab tests and specimens obtained within the state.

New York was the only state in the US to previously prohibit the firm from offering the test, which is marketed through a licensing agreement with Quest Diagnostics' subsidiary OralDNA Labs, to its residents.

The PST test identifies patients that have higher genetic risk for developing severe periodontal disease, which is the most common cause of tooth loss.

The firm said that the test is particularly useful for indicating which patients with early signs of periodontal disease, including gingivitis, and early to moderate periodontitis, are most likely to develop severe periodontitis and other complications.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.